Reimbursement for Mandatory Screening Services

The following blood lead screening services shall constitute the “Mandatory Blood Lead Screening” in accordance with 105 CMR 460.050 and is required to be covered under policies of insurance as provided by M.G.L. c. 175, § 47C, hospital service contracts as provided by M.G.L. c. 176A, § 8B, medical service contracts as provided by M.G.L. c. 176B, § 4C, and health maintenance contracts as provided by M.G.L. c. 176G, § 4, and shall be reimbursable: (A) Assessment of the child for regular screening at age four, in accordance with 105 CMR 460.050(C), and assessment for high-risk screening, in accordance with 105 CMR 460.050(D). (B) Completion of the laboratory form known as a bloodslip. (C) Drawing of the blood specimen pursuant to 105 CMR 460.050(B). (D) Packaging and handling of the blood specimen including postage costs for mailing the specimen to the laboratory. (E) Analysis of the blood specimen for lead level by atomic absorption spectrophotometry or any other method approved by the Clinical Laboratory Improvement Amendments of 1988, Public Law 100-578, to § 353 of the Public Health Service Act, 42 U.S.C. 263a, and for erythrocyte protoporphyrin by fluorometry, either through the measurement of zinc protoporphyrin or by extraction.